FRANKFURT, GERMANY – Bayer AG announced today that it is stopping worldwide sales of Trasylol, used to reduce bleeding, because a Canadian clinical study found use of the drug could increase risk of death. Trasylol is an aprotinin, which blocks enzymes that dissolve blood clots. In October, the U.S. FDA allowed Trasylol to remain on the market despite studies that showed increased risk of death and other side effects.
- Shareholder Class Actions
- Former Explorer Scouts’ Sex Abuse Claims Against Los Angeles Are Time-Barred